Daniel Shuster, DO
Vascular Neurology · Royal Oak, MINPI 1326573361
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $170 and has fallen 89.8% since, to $17 in 2025. That places this record below the midpoint for vascular neurology clinicians in MI, where the typical reported total is $1,265.
Across 17 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$54
- AbbVie$50
- Avanir Pharmaceuticals, Inc.$36
- Mallinckrodt Enterprises LLC$35
- Genentech USA, Inc.$28
- Neurelis, Inc.$23
- plus $83 from 5 others
What the payments were for
- Food & beverage$309100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 3 | $54 |
| AbbVie | 3 | $50 |
| Avanir Pharmaceuticals, Inc. | 2 | $36 |
| Mallinckrodt Enterprises LLC | 2 | $35 |
| Genentech USA, Inc. | 1 | $28 |
| Neurelis, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $22 |
| Livanova USA, Inc. | 1 | $17 |
| Vertical Pharmaceuticals, LLC | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Saol Therapeutics Inc. | 1 | $12 |
How this compares
$309 in reported general payments places this provider in the 15th percentile of 29 vascular neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $17,916 |
| Atorvastatin Calcium | 86 | $1,102 |
| Rosuvastatin Calcium | 29 | $438 |
| Propranolol Hcl ErPropranolol Hcl | 13 | $424 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 15 | $385 |
| Levetiracetam | 16 | $379 |
| ClopidogrelClopidogrel Bisulfate | 24 | $226 |
| Donepezil Hcl | 38 | $216 |
| Gabapentin | 32 | $199 |
| Losartan Potassium | 11 | $189 |
Paid to pharmacies, not to this prescriber.
Other vascular neurology in Royal Oak
- Mounzer Yassin KassabEast Lansing$443K
- Aniel MajjhooFlint$432K
- David RosenbaumTraverse City$121K
- Anmar RazakEast Lansing$86K
- Surindar JollyWayne$25K
- Fazeel SiddiquiWyoming$14K
- Dawn KleindorferAnn Arbor$7K
- Daniel MillerDetroit$5K
- Jiangyong MinGrand Rapids$4K
- George DillonClinton Township$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.